ReviewCancer science2026
Evolving Pathology of Anaplastic Thyroid Carcinoma: Integrating Morphology, Immunohistochemistry, and Molecular Insights.
Review in Cancer science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Anaplastic thyroid carcinoma (ATC) is a rare malignancy characterized by an extremely aggressive clinical course, in contrast to the typically indolent behavior of most thyroid carcinomas. Recent advances in high-throughput sequencing technologies have markedly enhanced our understanding of the genetic alterations underlying ATC. These molecular insights have also influenced current clinical management and pathologic classification. In diagnostic pathology, squamous cell carcinoma arising in the thyroid is now recognized as a histologic variant of ATC. The BRAF p.V600E mutation, detected in approximately half of ATCs, represents a clinically significant genetic alteration, as targeted therapies directed against this mutation have been associated with improved clinical outcomes. In addition to advances in molecular pathology, progress has also been made in diagnostic pathology, including expanded recognition of the histologic spectrum of ATC and the development of novel immunohistochemical markers. In this review, we summarize recent advances in the diagnostic and molecular pathology of ATC, aiming to provide both fundamental and practical insights for clinical practice. In diagnostic pathology, ATC often presents significant challenges because of its marked histologic heterogeneity and a broad differential diagnosis. Accordingly, this review provides an overview of both classical knowledge and recent molecular findings related to ATC and integrates these insights to present an updated framework for differential diagnosis and diagnostic approach. In addition, we discuss recent advances in immunohistochemistry, including mutation-specific antibodies and novel diagnostic markers, and highlight their relevance in the context of contemporary diagnostic pathology and evolving therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.